i-SENS, Inc (099190) Fair Value & Analysis
Healthcare · KR · Market cap 445B KRW
Fair value as of: Jul 22, 2026
From 6 valuation models · updated 19 days ago
Fair value updated Jul 22, 2026, revised from 7,911 KRW to 8,168 KRW (+3.3%) since Jul 5, 2026. Share price +24.0% over the past month.
Below-average quality, and screening another 57% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (8,168 KRW). The favourable scenario is already priced in.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
- Solid but not exceptional quality (49/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 22, 2026.
How to read this chart
60‑month range 11,777 KRW – 38,070 KRW · fair‑value band 4,986 KRW – 8,168 KRW · the 18,870 KRW price screens above the 8,168 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 22, 2026.
Analysis
i-SENS, Inc (099190) currently trades at 18,870 KRW, while our model-based Fair Value estimate is 8,168 KRW, implying the stock looks roughly 56.7% overvalued today. The Quality Score stands at 49/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Over the trailing twelve months, i-SENS, Inc generated revenue of 262B KRW at a net margin of 7.7%. Revenue grew 16.1% year over year. It earns a return on equity of 35.3%. Net debt stands at 126B KRW. Fundamentals as of Jul 22, 2026
Our scenario range runs from 4,986 KRW (bear case) to 8,168 KRW (bull case); at 18,870 KRW, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 32% below its 52-week high and 29% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -2% fair-value upside, at -57%, 099190 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 6 models by family
Widest divergence: Asset-Based (7,657 KRW) versus Earnings-Based (1,083 KRW). Highest evidence: ROIC Compounder (72).
Notify me when 099190 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 22, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 44 · Market factors (momentum, volatility) 42
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
i-SENS, Inc. provides diagnostic biosensors in South Korea. The company offers point of care testing devices, such as HbA1c, blood gas, electrolyte, and PT/INR analyzers; CareSens blood glucose monitoring systems; and lancing and other ancillary devices, as well as diabetes management services.
Full company description
i-SENS, Inc. provides diagnostic biosensors in South Korea. The company offers point of care testing devices, such as HbA1c, blood gas, electrolyte, and PT/INR analyzers; CareSens blood glucose monitoring systems; and lancing and other ancillary devices, as well as diabetes management services. It exports its products to approximately 110 countries, including the United States, Japan, and Europe. The company was founded in 2000 and is headquartered in Seoul, South Korea.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
i-SENS, Inc reported revenue of 315B KRW in FY2025 versus 233B KRW in FY2021, a compound +7.9%/yr. Reported net income was −5.1B KRW in FY2025.
099190 screens 57% overvalued. Compare with InBody Co →
Peer Group
Health Care · 2227 stocks
How this stock ranks against its sector: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median. (Industry “Healthcare Equipment & Supplies” was too small, so the broader sector is used.)
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Healthcare Equipment & Supplies stocks, each showing price versus our Fair Value estimate (as of Jul 22, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| InBody Co 041830 | 50,900 KRW | 49,984 KRW | -2% |
| Value Added Technology Co 043150 | 16,800 KRW | 60,242 KRW | +259% |
| Mediana Co 041920 | 8,940 KRW | 6,289 KRW | -30% |
| Meta Biomed Co 059210 | 3,830 KRW | 9,875 KRW | +158% |
| Sewoon Medical Co 100700 | 2,245 KRW | 6,054 KRW | +170% |
| MEDIC MEDIC | 0.2100 PHP | 0.1400 PHP | -33% |
| MEKICS CO., Ltd 058110 | 1,780 KRW | 1,584 KRW | -11% |
| CU Medical Systems, Inc 115480 | 1,753 KRW | 1,134 KRW | -35% |
| PeopleBio, Inc 304840 | 857.00 KRW | 905.70 KRW | +6% |
| Novartis AG NVSN | 2,742 MXN | 2,379 MXN | -13% |
Compare i-SENS, Inc with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is i-SENS, Inc (099190) overvalued or undervalued?
What is the fair value of 099190?
What is the quality score of 099190?
What is the revenue of i-SENS, Inc (099190)?
What is the net profit margin of 099190?
Does i-SENS, Inc pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track i-SENS, Inc and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.